Specific monoclonal antibody-based immunotherapy by targeting the RCC-associated antigen carbonic anhydrase-IX(G250/MN).
Mulders
Peter
P
Department of Urology, Radboud University Nijmegen, Nijmegen, The Netherlands. p.mulders@uro.azn.nl
Bleumer
I
I
Debruyne
F
F
Oosterwijk
E
E
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000918:Antibody Specificity / Q000276:immunology*; D000951:Antigens, Neoplasm / Q000276:immunology*; D000071231:Carbonic Anhydrase IX; D002256:Carbonic Anhydrases / Q000276:immunology*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000276:immunology; D002986:Clinical Trials as Topic; D003601:Cytotoxicity Tests, Immunologic; D004305:Dose-Response Relationship, Drug; D016503:Drug Delivery Systems; D004359:Drug Therapy, Combination; D006801:Humans; D007376:Interleukin-2 / Q000009:adverse effects / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000276:immunology; D009362:Neoplasm Metastasis; D000069283:Rituximab; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000951:Antigens, Neoplasm; C106533:G250 monoclonal antibody; D007376:Interleukin-2; D000069283:Rituximab; C089226:CA9 protein, human; D000071231:Carbonic Anhydrase IX; D002256:Carbonic Anhydrases; D000068878:Trastuzumab